The advent of novel nonsteroidal mineralocorticoid receptor antagonists in heart failure - PACE-CME

The advent of novel nonsteroidal mineralocorticoid receptor antagonists in heart failure

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Tirzepatide reduces HF events in patients with HFpEF and obesity
Tirzepatide reduces HF events in patients with HFpEF and obesity
AHA 2024
Tirzepatide reduces HF events in patients with HFpEF and obesity
- Milton Packer, MD
Acoramidis reduces all-cause mortality in ATTR-CM
Acoramidis reduces all-cause mortality in ATTR-CM
AHA 2024
Acoramidis reduces all-cause mortality in ATTR-CM
- Daniel Judge, MD
Audit and feedback strategy for pharmacists improves HF care
Audit and feedback strategy for pharmacists improves HF care
AHA 2024
Audit and feedback strategy for pharmacists improves HF care
- Alexander Sandhu, MD
Mastering MRA Monitoring: The Key to Success
Mastering MRA Monitoring: The Key to Success
MinuteCE®
Mastering MRA Monitoring: The Key to Success
1.25 program credits
- Akshay S. Desai, MD
- John McMurray, MD
1.25 program credits